Related Experiment Video
Updated: Jul 18, 2026

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
Published on: February 8, 2019
Activating and inhibitory FcgammaRs in autoimmune disorders
1Laboratory of Molecular Genetics and Immunology, 1230 York Avenue, New York, NY, 10021, USA, nimmerf@rockefeller.edu.
Dysregulated Fc receptor (FcR) expression disrupts immune checkpoints, leading to autoimmune diseases. Understanding FcR balance is key to developing new therapies for these conditions.
Area of Science:
- Immunology
- Autoimmunity
- Molecular Biology
Background:
- Autoimmune disorders involve immune system attacks on the body's own tissues.
- Immune responses are regulated by checkpoints to prevent self-tissue destruction.
- Fc receptors (FcR) on immune cells act as critical checkpoints.
Purpose of the Study:
- To review evidence linking aberrant Fc receptor expression to autoimmune diseases.
- To explore the potential of FcR modulation for novel therapeutic strategies.
Main Methods:
- Review of data from murine model systems.
- Analysis of Fc receptor (FcR) expression in autoimmune conditions.
Main Results:
- Coexpression of activating and inhibitory Fc receptors (FcR) establishes an immune activation threshold.
- Disturbed FcR expression is observed in many human autoimmune diseases.
- Aberrant FcR expression in murine models correlates with uncontrolled immune responses and autoimmune initiation.
Conclusions:
- Fc receptor (FcR) dysregulation is a significant factor in autoimmune disease pathogenesis.
- Targeting Fc receptor pathways offers potential for developing new autoimmune disease treatments.
Related Concept Videos
Autoimmune Disorders
Concept and Mechanism of Autoimmune Diseases
The immune system...
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Myasthenia Gravis ll: Pathophysiology
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Immunoglobulin-like Cell Adhesion Molecules
Ig-CAMs exhibit either homophilic binding (to other Ig-CAMs) or heterophilic binding (to other ligands such as integrins). While most Ig-CAMs...